Skip to main content
    T

    Teladoc Inc (TDOC)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NYSE

    $8.80
    +0.11 (+1.27%)

    Market Cap: $1.60B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Teladoc Inc (TDOC) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Teladoc (TDOC) trades at 0.6x sales and 1.2x book value. Its P/S of 0.6x is below its 5-year median of 0.8x. Its forward P/E is 303.0x.

    Current Multiples

    Its enterprise value is 8.4x its EBITDA. Its free cash flow yield is 8.7%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E303.0x
    Price to sales0.6x
    Price to book1.2x
    EV/EBITDA8.4x
    Price to FCF11.5x
    EV/FCF12.8x
    PEGN/A
    FCF yield8.7%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 91.4% below 7.0x and its P/B is 29.4% below 1.7x.

    MultipleCurrent5-year median10-year median
    P/S0.6x0.8x7.0x
    P/B1.2x1.0x1.7x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 0.5x in 2025 to 16.6x in 2020. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$7.000.5x0.9x
    2024$9.090.6x1.1x
    2023$21.551.4x1.5x
    2022$23.651.6x1.7x
    2021$91.827.1x0.9x
    2020$199.9616.6x1.6x
    2019$83.7210.9x6.0x
    2018$49.577.8x3.4x
    2017$34.858.3x3.6x
    2016$16.505.9x3.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TDOC

    What is TDOC's forward P/E ratio?

    Teladoc has a forward P/E ratio of 303.0x.

    Is TDOC stock overvalued?

    GNG's valuation label for TDOC is Fairly valued.

    What is TDOC's price to sales ratio?

    Teladoc has a price to sales ratio of 0.6x.